Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever
Item
Click for External Resource*
Click to read full article*
*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.
Files for Download
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682919/pdf/nihms904566.pdf
- Item Type
- Publication
- Terms of Use
- By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.
Stable Link to this Asset
Example only: NETEC provides this item for reference purposes but does not endorse its content. Newer versions may be in place at the providing institution.
Document Viewer
Information about this resource
- Title
- Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever
- Subject
- Treatment & Care
- Description
- Two patients with Lassa fever are described who are the first human cases treated with a combination of ribavirin and favipiravir.
- Date
- 2017-09-01
- Citation
- Raabe, V. N., G. Kann, B. S. Ribner, A. Morales, J. B. Varkey, A. K. Mehta, G. M. Lyon, S. Vanairsdale, K. Faber, S. Becker, M. Eickmann, T. Strecker, S. Brown, K. Patel, P. De Leuw, G. Schuettfort, C. Stephan, H. Rabenau, J. D. Klena, P. E. Rollin, A. McElroy, U. Stroher, S. Nichol, C. S. Kraft, T. Wolf and U. Emory Serious Communicable Diseases (2017). "Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever." Clin Infect Dis 65(5): 855-859.
- Abstract
- Two patients with Lassa fever are described who are the first human cases treated with a combination of ribavirin and favipiravir. Both patients survived but developed transaminitis and had prolonged detectable virus RNA in blood and semen, suggesting that the possibility of sexual transmission of Lassa virus should be considered.
- Accessibility
- free online - Pubmed Central
Was this resource helpful?